Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA)

a technology of rna oligonucleotide and double-stranded rna, which is applied in the field of topical administration of at least one double-stranded rna oligonucleotide (dsrna), can solve the problems of inability to achieve the quantity, application limitations, and inability to achieve desirable effects, and achieve the effect of reducing the quantity of double-stranded rna oligonucleo
US20050222071A1Inactive Publication Date: 2005-10-06LOREAL SA
3 Cites 35 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
LOREAL SA
Publication Date
2005-10-06
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefor; such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and / or differentiation, etc.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO PRIORITY / PCT / PROVISIONAL APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119 of FR-02 / 06796, filed Jun. 3, 2002, and of provisional application Ser. No. 60 / 386,720, filed Jun. 10, 2002, and is a continuation of PCT / FR 2003 / 001648, filed Jun. 2, 2003 and designating the United States (published in the French language on Dec. 11, 2003, as WO 2003 / 101376 A3; the title and abstract were also published in English), each hereby expressly incorporated by reference and each assigned to the assignee hereof.BACKGROUND OF THE INVENTION

[0002] 1. Technical Field of the Invention

[0003] The present invention relates to the administration of at least one double-stranded RNA oligonucleotide (dsRNA) via topical application and to compositions for topical administration which comprise at least one encapsulated double-stranded RNA oligonucleotide formulated into a physiologically acceptable medium therefor.

[0004] 2. Description of Background and / or Related a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More